Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards

PR Newswire

PLAINSBORO, N.J., Nov. 17, 2026

PLAINSBORO, N.J., Nov. 17, 2026 /PRNewswire/ -- Novo Nordisk, the maker of Wegovy® (semaglutide) injection and tablets, today announced a reimagined consumer experience to help people get started and stay supported on Wegovy®. Novocare® brings together treatment and coverage information, fast and free home delivery and a new app to help track progress, provide personalized support, and share information about its partners and their services and offers. Novo continues to pair innovation with putting patients at the center of everything it does, evolving Novocare® to offer more personal, connected support. People can learn more and join for free at JoinNovocare.com. 

"Novo has been a scientific leader in the development of innovative medicines for more than a century. Now we're taking our people-centered approach to the next level with Novocare®, deepening our relationship with those interested in our medicines and the healthcare professionals who prescribe them," said Ed Cinca, Senior Vice President of Marketing and Patient Solutions at Novo. "We're helping people get started on treatment and stay supported with tools and resources that go well beyond the prescription, even as their needs evolve. This is just the beginning of how we show up for the people we serve, with more partners and services to come."

What is Novocare® and how does it support a person's weight loss?

Novocare® is a free membership experience that connects people with weight-loss treatment information, access to Wegovy® home delivery, tools and everyday support through a website and also an app. Members can:

Which partners are available through Novocare®?

Support beyond the prescription, built around everyday life: Weight loss can bring changes to people, ranging from eating habits and activities to how they feel in their clothes. Novocare® connects members with partners offering practical resources for these everyday changes†:

Partner services, costs and eligibility requirements vary. Additional partners are planned over time.

"What happens after someone receives a prescription matters just as much as the prescription itself. Too often, I've heard people talk about how they leave an appointment with questions that often go beyond how to take their medicine," said Alexandra Sowa, MD, Obesity Medicine Physician and founder of the SoWell Method. "Education is one of the most important parts of a person's health and wellness, and having a reliable place to turn for practical guidance can help people feel more confident making treatment part of their daily lives. Such support can complement, not replace, the care they receive from their physician."

Coming soon to Novocare®

Progress toward long-term health starts with helping people find the tools and support they need today. Novocare® will continue to expand, bringing together treatment access, support, information and practical resources to help people navigate care and everyday routines as their needs change.

The Novocare® website will continue to provide cost and coverage information for Novo treatments in other therapeutic areas outside of obesity. Novocare® continues to provide services such as home delivery for eligible Ozempic® (semaglutide) prescriptions.

For more information or to join for free, visit JoinNovocare.com or download the Novocare® app.

* Eligibility, terms and conditions will apply.

†Partnerships are for informational purposes only and do not constitute an endorsement of any particular healthcare professional, meal plan, wearable device, exercise program or other product or service. The companies and providers referenced are independent of Novo and represent some options among many that are or will be available to patients. Patients should make their own independent decisions regarding the suitability of any provider, product or service. Please consult with a healthcare professional for guidance on questions related to health, nutrition, fitness, exercise or medical treatments. 

What is Wegovy®?

Wegovy® (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:

Wegovy® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:

Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy® injection is safe and effective:

It is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age.

Important Safety Information

What is the most important information I should know about Wegovy®?
Wegovy® may cause serious side effects, including:

Do not use Wegovy® if:

Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

What are the possible side effects of Wegovy®?
Wegovy® may cause serious side effects, including:

The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.

Please see Prescribing Information including Boxed Warning and Medication Guide for Wegovy®.

Wegovy® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Ozempic®?

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Ozempic® (semaglutide) tablets 4 mg or 9 mg are prescription medicines used:

Ozempic® injection is used:

Ozempic® tablets are used:

It is not known if Ozempic® injection and Ozempic® tablets are safe and effective for use in children.

Important Safety Information for Ozempic®

Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.

What is the most important information I should know about Ozempic®?

Ozempic® may cause serious side effects, including:

Do not use Ozempic® if:

Before using Ozempic®, tell your health care provider if you have any other medical conditions, including if you:

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.

What are the possible side effects of Ozempic®?

Ozempic® may cause serious side effects, including:

The most common side effects of Ozempic® may include nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation. When taking Ozempic® tablets, they may also include decreased appetite.

Please see Prescribing Information including Boxed Warning and Medication Guide for Ozempic® injection.

Please see Prescribing Information including Boxed Warning and Medication Guide for Ozempic® tablets.

Ozempic® injection and Ozempic® tablets are prescription medications.

Novo Nordisk provides patient assistance for those who qualify. Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we've combined leading scientific expertise with a deep understanding of people's lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programs and investments, we're working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. In the United States, Novo has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people. For more information, visit novonordisk.com and novonordisk-us.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Contacts for further information:

Novo Media:


Ambre James-Brown

+45 3079 9289
globalmedia@novonordisk.com           

Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com


Novo Investors:


Michael Novod

+45 3075 6050
nvno@novonordisk.com

Sina Meyer

+45 3079 6656
azey@novonordisk.com

Max Ung

+45 3077 6414

mxun@novonordisk.com

Christoffer Togo Solgaard-Tullin

+45 3079 1471
cftu@novonordisk.com 

Ida Schaap Melvold

+45 3077 5649

idmg@novonordisk.com

Mads Berner Bruun

+45 3075 2936
mbbz@novonordisk.com

Frederik Taylor Pitter (US)

+1 609 613 0568
fptr@novonordisk.com

Alex Bruce (US)

+1 640 230 0276
axeu@novonordisk.com

© 2026 Novo Nordisk All rights reserved. US26NC00279 November 2026

Novo Nordisk, Inc.  (PRNewsFoto/Novo Nordisk)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-launches-the-new-novocare-free-support-program-connects-people-with-wegovy-in-addition-to-home-delivery-everyday-support-wellness-partners-and-rewards-302941304.html

SOURCE NOVO NORDISK INC.